Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement




Apr
08
Today In Oncology
Analysis Shows Nearly 7 Percent of Global Clinical Trials Are Impacted by Middle East Conflict
Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer
Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer
Ablative Radiotherapy May Improves Outcomes for Patients With Large Intrahepatic Cholangiocarcinoma
Setidegrasib in Advanced NSCLC and Pancreatic Cancer Harboring the KRAS p.G12D Variant
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo